Disease-associated antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2

Xaquín Castro Dopico[1#], Leo Hanke[1°], Daniel J. Sheward[1°], Murray Christian[1], Sandra Muschiol[2], Nastasiya F. Grinberg[3], Monika Adori[1], Laura Perez Vidakovics[1], Kim Chang Il[1], Sharesta Khoenkhoen[1], Pradeepa Pushparaj[1], Ainhoa Moliner Morro[1], Marco Mandolesi[1], Mattias Forsell[4], Jonathan Coquet[1], Martin Corcoran[1], Joanna Rorbach[5,6], Soo Aleman[7], Gordana Bogdanovic[2], Gerald McInerney[1], Tobias Allander[1,2], Chris Wallace[3,8], Ben Murrell[1*], Jan Albert[1,2*], Gunilla B. Karlsson Hedestam[1#]

Affiliations:
[1]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
[2]Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
[3]Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW
[4]Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden
[5]Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden
[6]Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden
[7]Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
[8]MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 0SR, United Kingdom

°*Equal contribution
#Correspondence

Abstract

Serological studies are critical for understanding pathogen-specific immune responses and informing public health measures[1,2]. By developing highly sensitive and specific trimeric spike (S)-based antibody tests, we report IgM, IgG and IgA responses to SARS-CoV-2 in COVID-19 patients (*n*=105) representing different categories of disease severity. All patients surveyed were IgG positive against S. Elevated anti-SARS-CoV-2 antibody levels were associated with hospitalization, with IgA titers, increased circulating IL-6 and strong neutralizing responses indicative of intensive care status. Antibody-positive blood donors and pregnant women sampled during the pandemic in Stockholm, Sweden (weeks 14-25), displayed on average lower titers and weaker neutralizing responses compared to patients; however, inter-individual anti-viral IgG titers differed up to 1,000-fold. To provide more accurate estimates of seroprevalence, given the frequency of *weak responders* and the limitations associated with the dichotomization of a continuous variable[3,4], we used a Bayesian approach to assign likelihood of past infection without setting an assay cut-off. Analysis of blood donors (*n*=1,000) and pregnant women (*n*=900) sampled weekly demonstrated SARS-CoV-2-specific IgG in 7.2% (95% Bayesian CI [5.1 – 9.5]) of individuals two months after the peak of spring 2020 COVID-19 deaths. Seroprevalence in these otherwise healthy cohorts increased steeply before beginning to level-off, following the same trajectory as the Stockholm region deaths over this time period.

Introduction

As SARS-CoV-2 only recently crossed the species barrier[5], populations globally were immunologically naïve to the virus. Characterizing the antibody response to nascent outbreaks is, therefore, central to optimizing approaches to tackle COVID-19 and future pandemics, furthering our basic understanding of human immunology[6–8].

To date, numerous SARS-CoV-2 studies have reported seroprevalence and disease-associated antibody phenotypes[9–11], isolated virus-neutralizing monoclonal antibodies[12–15] and used convalescent individuals to define metrics for plasma therapy[16]. However, consensus on several key issues remains outstanding. For instance, the majority of serology data are derived from commercial kits utilizing SARS-CoV-2 spike derivatives (e.g. RBD, S1 or S2 domains) or the nucleocapsid to detect pathogen-specific antibodies[9,17,18]. Several of these assays suffer from epitope loss[19], increased cross-reactivity[9,20] and lower sensitivity[21], highlighting the need for comparative studies to identify optimal assay formats for individual and population level analysis[22–24]. Here, we developed a highly sensitive and specific ELISA assay based on native-like prefusion-stabilized spike trimers[25], as well as the receptor-binding domain (RBD), to accurately evaluate anti-viral antibody levels in COVID-19 patients and key community groups. To identify disease-associate antibody phenotypes, anti-viral IgM, IgG and IgA levels were analyzed alongside *in vitro* virus neutralisation capacity and a descriptive set of clinical features, including intensive care status.

A major consideration for antibody testing concerns setting the cut-off for positivity[26–28], which significantly affects seroprevalence estimates and individual clinical management. Currently employed approaches to the problem are severely limited by their high dependency on the representative nature of negative control values and the dichotomization of a continuous variable. Therefore, to obtain more accurate seroprevalence estimates in blood donors and pregnant women, we strictly controlled our assay with a large number of historical controls (n=295) and used our patient data to train probabilistic algorithms to handle ELISA data. We used our cut-off-independent approach to model population changes in seropositivity over time.

We sampled blood donors and pregnant women weekly throughout the outbreak. Blood donors serve as an important clinical resource, including for potential COVID-19 plasma therapies, while pregnant women require close clinical monitoring with respect to fetal-maternal health and are known to employ unique, yet poorly characterized immunological mechanisms that impact infectious pathology[29–31]. As Sweden did not impose a strict lockdown in response to the pandemic and has reported relatively high per-capita morbidity and mortality (ECDC, EU), understanding

90 SARS-CoV2 seroprevalence in these cohorts helps plan clinical need and understand
91 the development of immunity in the population.
92

Results

Anti-SARS-CoV-2 antibody phenotypes in COVID-19 patients, blood donors and pregnant women

To evaluate humoral immune responses to SARS-CoV-2, we developed ELISA protocols to profile IgM, IgG and IgA directed against a stabilized trimeric form of the spike (S) glycoprotein[25], its receptor binding domain (RBD) and the nucleocapsid protein. The two spike-based antigens were produced in mammalian cells in-house (Fig S1A) and S trimer conformation was confirmed by cryo-EM analysis[32].

The study as a whole, included sera from SARS-CoV-2 PCR-positive COVID-19 patients (*n*=105) representing different disease categories, current blood donors (*n*=1,000) and pregnant women (*n*=900) sampled during 2020, hereafter referred to as healthy donors, historical blood donors collected during spring 2019 (*n*=295) and individuals shown to be PCR+ for endemic coronaviruses (ECV+, *n*=20) (Table 1 and Materials and Methods). We used a subset of these samples as a validation set for assay optimization, comprising samples from COVID-19 patients (*n*=36) and two sets of negative controls, 2019 blood donors (*n*=75) and ECV+ individuals (*n*=20).

All COVID-19 patients in the validation set displayed IgG responses to the S antigen and almost all responded to RBD, albeit less strongly (Fig S1B and S2A). No reactivity was recorded for the negative control samples, except for two ECV+ individuals who displayed reproducible IgM reactivity to SARS-CoV-2 nucleocapsid and S, and two 2019 blood donors with weak anti-S IgM reactivity (Fig S1C and S2). Further investigation is required to establish the basis of these observations and whether cross-reactive memory or primordial lymphocyte lineages contribute to SARS-CoV-2 responses *a priori*.

Our assay revealed up to a 1000-fold difference in anti-viral antibody IgG titers between individuals when examining serially diluted sera (Fig S2). In patients, anti-viral IgG titers were comparable for S (EC_{50}=3,064; 95% CI [1,197 - 3,626]) and nucleocapsid (EC_{50}=2,945; 95% CI [543 - 3,936]) and lower for RBD [EC_{50}=1,751; 95% CI 966 - 1,595]. A subset (approximately 10%) of patients did not have detectable IgG responses to the nucleocapsid (Fig S2), in agreement with previous studies[9].

We next screened all SARS-CoV-2 PCR+ COVID-19 patients in the study (*n*=105) and detected potent IgG responses against S in all individuals and against RBD in all but a 3% individuals (Fig 1A and S3A). When screening the healthy blood donor and pregnant cohorts, we observed a subset of individuals who were clearly seropositive against SARS-CoV-2, but the titers against S and RBD that were generally lower than those measured in COVID-19 patients (Fig 1A and S3A). However, IgG titers in this

group varied greatly, with some persons displaying levels similar to those measured in COVID-19 patients while others had titers similar to those observed at the higher end of the historical negative control range. This group of *weak responders* highlighted the challenge of using a pre-determined assay cut-off, a critical point that we address and present potential solutions for in Figure 4.

When examining IgM and IgA responses against S and RBD, we found them to be less potent and more variable between individuals than the IgG response (Fig 1B and S3B). Given their unique immunological roles and what is known about COVID-19 pathology, we sought to investigate whether isotype responses segregated with clinical features. Therefore, the COVID-19 patient cohort was classified according to clinical disease severity: Category 1 – *non-hospitalized*; Category 2 – *hospitalized*; Category 3 – *intensive care* (on mechanical ventilation) (Table 1).

Within-patient anti-S and anti-RBD responses were highly correlated for all three isotypes (Fig S3C). Furthermore, multivariate analyses showed that increased anti-viral IgM, IgG and IgA levels significantly correlated with disease severity (Fig 1C, S3D and S Table 1), in line with the lower titers observed in blood donors and pregnant women. This was most pronounced for pathogen-specific IgA, suggestive of advancing mucosal disease[33]. A more severe clinical picture was also strongly associated with elevated serum IL-6 (Fig 1C), a cytokine that feeds antibody production[34–37]. IL-6 is dysregulated in polygenic metabolic diseases[38–40] and acute respiratory distress syndrome (ARDS)[41], which are risk factors for COVID-19-associated mortality[42,43]. Notably, under univariate analysis, female patients showed lower anti-viral IgA levels than males in non-hospitalized and hospitalized groups, which was also true for anti-RBD IgA in multivariate analysis (Fig S4A)[44]. Overall, severity showed the most consistent relationship with any measure and was the primary driver of Ig levels.

To summarize patient antibody phenotypes, we generated a Spearman's rank correlation matrix (Fig 2A), which highlights a negative association between patient date of birth and all dataset features, in-keeping with the worse prognosis for elderly COVID-19 patients, as well as a lack of association between serum IL-6 and anti-viral IgM levels, further supporting that levels of the cytokine and IgA mark a protracted, more severe clinical course. After accounting for the effect of age, sex and days since PCR+ test, anti-viral IgA titers were approximately 3-fold higher in intensive care vs. non-hospitalized patients, while IL-6 levels were *ca.* 10-fold increased (Fig 2B). Notably, we also detected low levels of anti-viral IgA when analyzing a small subset (n=100) of healthy donors from this year (Fig S4B).

Critical future studies are required to establish the longevity of immunity to SARS-CoV-2, including the efficacy of cellular re-call responses, as detectable antibody titers

177 decline in the absence of antigen[45]. Here, anti-viral IgG levels were maintained two
178 months post-disease onset/positive PCR test, while IgM and IgA declined (Fig S4C),
179 in agreement with their circulating $t_{1/2}$[46] and reflecting their diagnostic utility. Patient
180 serum was collected 6-61 days post-PCR (Fig S4D), with the median time from
181 symptom onset to PCR test being 5 days. In longitudinal patient samples where we
182 observed seroconversion, IgM, IgG and IgA peaked with similar kinetics when all three
183 isotypes developed, although anti-viral IgA was not always generated in Category 1
184 and 2 patients (Fig 1D and S4E). We note that anti-viral IgM could be maintained two
185 months post-PCR+/symptom onset (Fig S4E).
186
187 We next characterized virus neutralizing antibody responses in patients and healthy
188 donors, a key parameter for understanding the potential for protective humoral
189 immune responses and the selection of plasma therapy donors. Using an *in vitro*
190 pseudotype virus neutralisation assay, we detected neutralizing antibodies in the
191 serum of all COVID-19 patients, and in all except two healthy antibody-positive donors
192 (from *n*=56). A range of neutralizing ID_{50} titers is apparent in patients' serum
193 (geometric mean ID_{50}=1,330; 95% CI [837 – 2,112], Fig 3A), with binding and
194 neutralisation titers being highly correlated (Fig 2A). The strongest neutralizing
195 responses were observed in samples from patients in intensive care (Category 3)
196 (ID_{50}=5,058; 95% CI [2,422 - 10,564]), in keeping with their elevated and presumably
197 more developed antibody response (Fig 3B and 1C). Sera from healthy blood donors
198 and pregnant women also displayed neutralizing responses, but similarly to the
199 binding data, were generally less potent than that observed in COVID-19 patients
200 (ID_{50}=600; 95% CI [357 – 1,010] and ID_{50}=350; 95% CI [228 - 538], respectively, Fig
201 3C). Across the two antigens and three isotypes, anti-RBD IgG was most strongly
202 correlated with neutralization (Fig 3D).
203
204 <u>Community seroprevalence estimations</u>
205
206 As the Stockholm region is a busy metropolitan area and Sweden did not impose strict
207 lockdown in response to the emergence of SARS-CoV-2, we sought to better
208 understand the frequency and nature of anti-SARS-CoV-2 antibody responses in
209 healthy blood donors and pregnant women during weeks 14-25 (March 30 to June 22
210 2020) (Fig 4A).
211
212 By surveying a large number of historical controls (*n*=295) during assay development,
213 we identified a considerable number of samples with *weak reactor*-phenotypes, which
214 must be taken into account when setting the assay cut-off. When using a small set of
215 historical controls, such values may be missed, resulting in an incorrect cut-off that
216 significantly increases the uncertainty of individual and population seroprevalence
217 estimates. To illustrate this, we randomly sampled groups of 20 negative control
218 samples (from 890 measures in 295 individuals) and calculated seroprevalence in

blood and pregnant women from weeks 17-19 based on a 6SD cut-off. Depending on which 20 negative controls were sampled, the seroprevalence ranged from 5.7 to 8.7%, a 35% difference (Fig 4B). *Weak responder* status is likely influenced by many factors, including genetic background, health status, total serum Ig and protein levels, assay variability. Critically, test samples with low anti-viral titers may also fall into this range, highlighting the need to better understand the assay boundary. Taking a one-dimensional 6SD cut-off for anti-S IgG responses based on all 890 values from 295 negative donors, 7.7% of healthy donors tested positive two months after the peak of deaths in the country (Fig 4C).

To exploit individual antibody titers and improve our estimates, we modelled the probability that a sample is positive by training two parallel learners using our patient and historical control anti-S and -RBD data, rather than setting a one-dimensional cut-off. Our Bayesian approach for inferring seroprevalence without thresholds is described in Christian *et al*[47]. Briefly, we exploit a class-balance corrected Bayesian logistic regression to infer seroprevalence, using a modified Gaussian Process to construct a prior over seroprevalence trajectories, sharing information between weeks. Using this approach, which allowed us to model population changes over time, we found the steep increase in positivity at the start of the pandemic to slow between weeks 17-25, approximating 7.2% (95% equal tailed Bayesian credible intervals [5.1 – 9.5]) at the last time point and suggesting that humoral immunity to the virus develops slowly in these populations despite considerable virus spread in the community.

To confirm our novel Bayesian approach, we compared it to various machine learning algorithms, creating an ensemble SVM-LDA learner to maximize sensitivity, specificity and consistency across different cross-validation strategies, where the proportion of positives in the held-out test set was deliberately varied from the training set (*see* Materials and Methods). We obtained convergent results between these tools and our framework (Fig S5A). Strikingly, seroprevalence inferred using our Bayesian approach exhibited the same trajectory as Stockholm County deaths when lagged by two and half weeks (Fig S5B), allowing for the calculation of a seroprevalence case fatality rate in appropriately powered cohorts.

Furthermore, such probabilistic approaches that annotate uncharacterized uncertainty pave the way towards greater clinical utility for antibody measures. For example, individuals 50% likely to be antibody-positive according to the ensemble learner (Fig 4E) can targeted for further investigation (e.g. re-testing). These tools have the potential, therefore, to provide more qualitative individual antibody measurements.

Discussion

Serology remains the *gold standard* for estimating previous exposure to pathogens and benefits from a large historical literature[48]. When robust, it indicates whether an individual has mounted an adaptive immune response against a specific agent and is a strong predictor of an anamnestic response and quicker recovery upon re-infection. Anti-viral antibody responses are central for protection against re-infection and for the protective efficacy of successful vaccines[49].

Although the concept of herd immunity is based upon the study of antibodies, worryingly, there is little-to-no standardization (or validation) of many of the available SARS-CoV-2 antibody tests. Globally, hospital staff and health authorities are struggling with test choices, negatively impacting individual outcomes and efforts to contain the virus. There is no single ideal test, although some are more accurate, affordable and scalable than others, and it seems reasonable that an international body undertake more basic research-private collaborations to advise on best practice, provide reagents, and further research in the area.

Benefitting from a robust antibody test developed alongside a diagnostic clinical laboratory responsible for monitoring sero-reactivity during the pandemic, we profiled SARS-CoV-2 antibody responses in three cohorts of clinical interest. COVID-19 patients showed the highest anti-viral titers, developing augmented serum IgA and IL-6 with worsening disease, likely a consequence of age, sex and other risk factors, as well as prolonged immune stimulation, a higher infectious dose, and host genetics. Therefore, isotype-level measures may assist COVID-19 clinical management and determine, for example, whether all critically ill patients develop class-switched mucosal responses to SARS-CoV-2, potentially informing therapeutic delivery[50,51].

Our neutralisation data shows that patients and healthy donors who seroconvert develop antibody titers capable of preventing infection *in vitro*, demonstrating the beneficial role of immunoglobulins against SARS-CoV-2. Further research into the specific inflammatory molecules/pathways aggravating the disease course, however, would allow for more specific targeting and control of immunity, with IL-6 being a case-in-point (NCT04322773, NCT04359667), although the cytokine's role in orchestrating adaptive responses[52] may make its modulation a double-edged sword in some patients[53].

Outside of the severe disease setting, it is important to determine how many people have seroconverted to SARS-CoV-2. Blood donors and pregnant women are both good sentinels for population health, although they are not enriched for high-risk groups, such as public transportation employees, where rates of infection may be higher. Blood donors are generally working age, active and mobile members of society

with a good understanding of health, and the majority of pregnant women in Sweden would have been advised to take precautions against infectious diseases. However, interestingly, both groups showed a similar seroprevalence.

By tracking these cohorts over time, we modelled seroprevalence changes at the population level. We found a steep increase in antibody positivity at the start of the pandemic, which increased, although at a slower rate, in blood donors and pregnant women during subsequent weeks, in-line with a decreasing caseload and fatalities[54]. Indeed, ICU occupancy and deaths are a better proxy for viral spread than PCR+ diagnoses, which are highly dependent on the number of tests carried out, and we note the close approximation of our seroprevalence data to Stockholm County deaths (Fig S5B), illustrating the power of mortality data to infer seroprevalence and *vice versa*.

Together, our study defines key features of the humoral immune responses to emerging beta-coronaviruses, delineating disease features, while our seroprevalence data indicate that population immunity to SARS-CoV-2 develops slowly even in the absence of lockdowns, suggesting that classical serological herd immunity following natural infection will require a larger outbreak and higher clinical toll; notwithstanding yet unknown contributions from T lymphocytes and other lineages. Given the uniqueness of the approach in Sweden[55], these data may inform the management of future pandemics. More widely, given the high inter-individual variability in antibody responses to SARS-CoV-2, the genetic and environmental factors influencing individual antibody responses will be important to elucidate.

Materials and methods

Human samples and ethical declaration

Samples from COVID-19 patients (*n*=105) were collected through the Departments of Medicine and Clinical Microbiology at the Karolinska University Hospital and were handled and analyzed in accordance with approval by the Swedish Ethical Review Authority (registration no. 2020-02811). All personal identifiers were pseudo-anonymized, and clinical feature data were blinded to the researchers carrying out experiments until data generation was complete.

All patients in the study were confirmed PCR+ for SARS-CoV-2 by nasopharyngeal swab or upper respiratory tract sampling after being admitted to Karolinska University Hospital. As viral RNA CT values were determined using different qPCR platforms between patients, we did not analyze these alongside other available features. Patients were questioned about the date of symptom onset at their initial consultation and followed-up for serology during their care, up to 2 months post-diagnosis. In addition, longitudinal samples from 10 of these patients were collected to monitor seroconversion and isotype persistence.

Anonymized samples from blood donors (100/week) and pregnant women (100/week) were randomly selected and obtained from the department of Clinical Microbiology, Karolinska University Hospital. No metadata, such as age or sex information was available for these samples. Pregnant women were sampled as part of routine for infectious diseases screening during the first trimester of pregnancy. Blood donors (*n*=295) collected through the same channels a year previously were randomly selected for use as negative controls. Serum samples from individuals testing PCR+ for endemic coronaviruses, 229E, HKU1, NL63, OC43 (*n*=20, ECV+) in the prior 2-6 months, were used as additional negative controls. The use of these anonymized samples was approved by the Swedish Ethical Review Authority (registration no. 2020-01807).

Stockholm County death and Swedish mortality data was sourced from the ECDC and Swedish Public Health Agency, respectively.

Study samples are defined in Table 1.

Serum sample processing

Blood samples were collected from patients by the attending clinical team and serum isolated by the department of Clinical Microbiology. Samples were barcoded and

369 stored at -20°C until use. Serum samples were not heat-inactivated for ELISA
370 protocols but were heat-inactivated at 56°C for 60 min for neutralization experiments.
371
372 SARS-CoV-2 antigen generation
373
374 The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain
375 with a C-terminal T4 fibritin trimerization motif was obtained from[25]. The plasmid was
376 used to transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent
377 (Thermo Fisher Scientific). The ectodomain was purified from filtered supernatant on
378 Streptactin XT resin (IBA Lifesciences), followed by size-exclusion chromatography
379 on a Superdex 200 in 5 mM Tris pH 8, 200 mM NaCl.
380
381 The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned upstream of a Sortase A
382 recognition site (LPETG) and a 6xHIS tag, and expressed in 293F cells as described
383 above. RBD-HIS was purified from filtered supernatant on His-Pur Ni-NTA resin
384 (Thermo Fisher Scientific), followed by size-exclusion chromatography on a Superdex
385 200. The nucleocapsid was purchased from Sino Biological.
386
387 Anti-SARS-CoV2 ELISA
388
389 96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S, RBD or
390 nucleocapsid (100 µl of 1 ng/µl) in PBS overnight at 4°C. Plates were washed six times
391 with 300 ml PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk (Sigma).
392 Human serum samples were thawed at room temperature, diluted (1:100 unless
393 otherwise indicated), vortexed and incubated in blocking buffer for 1h before plating.
394 Serum samples were incubated overnight at 4°C before washing, as before.
395 Secondary HRP-conjugated anti-human antibodies were diluted in blocking buffer and
396 incubated with samples for 1 hour at room temperature. Plates were washed a final
397 time before development with TMB Stabilized Chromogen (Invitrogen). The reaction
398 was stopped using 1M sulphuric acid and OD values were measured at 450 nm using
399 an Asys Expert 96 ELISA reader (Biochrom Ltd.). Secondary antibodies (all from
400 Southern Biotech) and dilutions used: goat anti-human IgG (2014-05) at 1:10,000;
401 goat anti-human IgM (2020-05) at 1:1000; goat anti-human IgA (2050-05) at 1:6,000.
402 All assays of the same antigen and isotype were developed for their fixed time and
403 samples were randomized and run together on the same day when comparing binding
404 between patients. All data were log transformed for statistical analyses.
405
406 *In vitro* virus neutralisation assay
407
408 Pseudotyped viruses were generated by the co-transfection of HEK293T cells with
409 plasmids encoding the SARS-CoV-2 spike protein harboring an 18 amino acid
410 truncation of the cytoplasmic tail[25]; a plasmid encoding firefly luciferase; a lentiviral

411 packaging plasmid (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was
412 changed 12-16 hours post-transfection and pseudotyped viruses harvested at 48- and
413 72-hours, filtered through a 0.45 μm filter and stored at -80°C until use. Pseudotyped
414 neutralisation assays were adapted from protocols validated to characterize the
415 neutralization of HIV, but with the use of HEK293T-*ACE2* cells. Briefly, pseudotyped
416 viruses sufficient to generate ~100,000 RLUs were incubated with serial dilutions of
417 heat-inactivated serum for 60 min at 37°C. Approximately 15,000 HEK293T-ACE2
418 cells were then added to each well and the plates incubated at 37°C for 48 hours.
419 Luminescence was measured using Bright-Glo (Promega) according to the
420 manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration
421 time of 0.3s. The limit of detection was at a 1:45 serum dilution.
422
423 IL-6 cytometric bead array
424
425 Serum IL-6 levels were measured in a subset of PCR+ COVID-19 patient serum
426 samples (n=64) using an enhanced sensitivity cytometric bead array against human
427 IL-6 from BD Biosciences (Cat # 561512). Protocols were carried out according to the
428 manufacturer's recommendations and data acquired using a BD Celesta flow
429 cytometer.
430
431 Statistical analysis of patient data
432
433 All univariate comparisons were performed using non-parametric analyses (Kruskal-
434 Wallis, stratified Mann-Whitney, hypergeometric exact tests and Spearman rank
435 correlation), as indicated, while multivariate comparisons were performed using linear
436 regression of log transformed measures and Wald tests. For multivariate tests, all
437 biochemical measures (IL-6, PSV ID50 neut., IgG, IgA, IgM) were log transformed to
438 improve the symmetry of the distribution. As "days since first symptom" and "days
439 since PCR+ test" are highly correlated, we cannot include both in any single analysis.
440 Instead, we show results for one, then the other (Supplementary Table 1).
441
442 Probabilistic seroprevalence estimations
443
444 We employed two distinct probabilistic strategies for estimating seroprevalence
445 without thresholds, each developed independently. Our Bayesian approach is
446 explained in detail in Christian *et al*[47]. Briefly, we use a logistic regression over anti-
447 RBD and -S training data to model the relationship between the ELISA measurements
448 and the probability that a sample is antibody-positive. We adjust for the training data
449 class proportions and use these adjusted probabilities to inform the seroprevalence
450 estimates for each time point. Given that the population seroprevalence cannot
451 increase dramatically from one week to the next, we construct a prior over
452 seroprevalence trajectories using a transformed Gaussian Process, and combine this

with the individual class-balance adjusted infection probabilities for each donor to infer the posterior distribution over seroprevalence trajectories.

Our second approach was based on more traditional machine learning and statistical approaches, which we compared through ten-fold cross validation (CV): logistic regression, linear discriminant analysis (LDA), and support vector machines (SVM) with a linear kernel. Logistic regression and linear discriminant analysis both model log odds of a sample being case as a linear equation with a resulting linear decision boundary. The difference between the two methods is in how the coefficients for the linear models are estimated from the data. When applied to new data, the output of logistic regression and LDA is the probability of each new sample being a case.

Support vector machines is an altogether different approach. We opted for a linear kernel, once again resulting in a linear boundary. SVM constructs a boundary that maximally separates the classes (i.e. the margin between the closest member of any class and the boundary is as wide as possible), hence points lying far away from their respective class boundaries do not play an important role in shaping it. SVM thus puts more weight on points closest to the class boundary, which in our case is far from being clear. Linear SVM has one tuning parameter *C*, a cost, with larger values resulting in narrower margins. We tuned *C* on a vector of values (0.001, 0.01, 0.5, 1, 2, 5, 10) via an internal 5-fold CV with 5 repeats (with the winning parameter used for the final model for the main CV iteration). We also note that the natural output of SVM are class labels rather than class probabilities, so the latter are obtained via the method of Platt[56].

We considered three strategies for cross-validation:

- random: individuals were sampled into folds at random
- stratified: individuals were sampled into folds at random, subject to ensuring the balance of cases:controls remained fixed
- unbalanced : individuals were sampled into folds such that each fold was deliberately skewed to under or over-represent cases compared to the total sample

We sought a method that worked equally well across all cross-validation schemes, as the true proportion of cases in the test data is unknown and so a good method should not be overly sensitive to the proportion of cases in the training data.

We found most methods worked well, although logistic regression was sensitive to changes in the case proportion in the training data. We chose to create an ensemble method combining that with the highest specificity (LDA) and the highest sensitivity (SVM), defined as an unweighted average of the probabilities generated under SVM

and LDA. The ensemble learner had average sensitivity > 99.1% and average specificity 99.8%.

We then trained the ensemble learner on all 719 training samples and predicted the probability of anti-SARS-CoV-2 antibodies in blood donors and pregnant volunteers sampled in 2020. We inferred the proportion of the sampled population with positive antibody status each week using multiple imputation. We repeatedly (1,000 times) imputed antibody status for each individual randomly according to the ensemble prediction, and then analyzed each of the 1,000 datasets in parallel, combining inference using Rubin's rules, derived for the Wilson binomial proportion confidence interval[57].

Data and code availability statement

Data generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.

Author contributions

GKH and XCD designed the study, analyzed the results and wrote the manuscript with input from co-authors. JA, TA, SM, GB and SA provided the study serum samples and clinical information. LH, LPV, AMM, DJS, KCI, BM and GM generated SARS-CoV-2 antigens and pseudotyped viruses. XCD and MF developed the ELISA protocols and XCD generated the data. DJS and BM developed and performed the neutralization assay. MCh and BM developed the Bayesian framework. CW and NFG assisted with patient data statistical analyses and executed machine learning approaches. MA, SK, PP, MM, JC, MCo and JR carried out wet lab experiments and assisted with data analysis.

Acknowledgments

We would like to thank the study participants and attending clinical teams. Secondly, we extend our thanks to Björn Reinius, Marc Panas, Julian Stark, Remy M. Muts and Darío Solis Sayago for their input and discussion. Funding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 2017-00968) and NIH (agreement SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC (MC_UP_1302/5)

Conflict of interest

The study authors declare no competing interests related to the work.

References

1. Altman, D., Douek, D. & Boyton, R. What policy makers need to know about COVID-19 protective immunity. *Lancet* (2020) doi:https://doi.org/10.1016/S0140-6736(20)30985-5.
2. Mouquet, H. & Nussenzweig, M. C. Polyreactive antibodies in adaptive immune responses to viruses. *Cellular and Molecular Life Sciences* (2012) doi:10.1007/s00018-011-0872-6.
3. MacCallum, R. C., Zhang, S., Preacher, K. J. & Rucker, D. D. On the practice of dichotomization of quantitative variables. *Psychol. Methods* (2002) doi:10.1037//1082-989x.7.1.19.
4. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *British Medical Journal* (2006) doi:10.1136/bmj.332.7549.1080.
5. Zhu, N. *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2001017.
6. Davis, M. M. A Prescription for Human Immunology. *Immunity* vol. 29 835–838 (2008).
7. Winter, A. K. & Hegde, S. T. The important role of serology for COVID-19 control. *The Lancet Infectious Diseases* (2020) doi:10.1016/S1473-3099(20)30322-4.
8. London, A. J. & Kimmelman, J. Against pandemic research exceptionalism. *Science* (2020) doi:10.1126/SCIENCE.ABC1731.
9. Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* (2020) doi:10.1038/s41591-020-0897-1.
10. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin. Infect. Dis.* (2020) doi:10.1093/cid/ciaa344.
11. Tan, W. *et al.* Viral Kinetics and Antibody Responses in Patients with COVID-19. *J Clin* **doi: 10.11**, (2020).
12. Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. *Nature* (2020) doi:10.1101/2020.05.13.092619.
13. Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science (80-.).* (2020) doi:10.1126/science.abc5902.
14. Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* (2020) doi:10.1038/s41586-020-2380-z.
15. Seydoux, E. *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity* (2020) doi:10.1016/j.immuni.2020.06.001.
16. Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc. Natl. Acad. Sci. U. S. A.* (2020) doi:10.1073/pnas.2004168117.
17. Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. *Trends in Immunology* (2020) doi:10.1016/j.it.2020.03.007.
18. Van Elslande, J. *et al.* Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin. Microbiol.*

584 *Infect.* (2020) doi:10.1016/j.cmi.2020.05.023.
585 19. Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
586 Glycoprotein. *Cell* (2020) doi:10.1016/j.cell.2020.02.058.
587 20. Cheng, M. *et al.* Cross-reactivity of antibody against SARS-coronavirus
588 nucleocapsid protein with IL-11. *Biochem. Biophys. Res. Commun.* (2005)
589 doi:10.1016/j.bbrc.2005.10.088.
590 21. Özçürümez, M. K. *et al.* SARS-CoV-2 antibody testing—questions to be asked.
591 *J. Allergy Clin. Immunol.* (2020) doi:10.1016/j.jaci.2020.05.020.
592 22. GeurtsvanKessel, C. H. *et al.* Towards the next phase: evaluation of serological
593 assays for diagnostics and exposure assessment. *Nat Comms* **doi: 10.10**,
594 (2020).
595 23. Deeks, J. J. *et al.* Antibody tests for identification of current and past infection
596 with SARS-CoV-2. *Cochrane Database Syst. Rev.* (2020)
597 doi:10.1002/14651858.cd013652.
598 24. Traugott, M. *et al.* Performance of Severe Acute Respiratory Syndrome
599 Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of
600 Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests. *J. Infect.*
601 *Dis.* (2020) doi:10.1093/infdis/jiaa305.
602 25. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
603 conformation. *Science (80-.).* (2020) doi:10.1126/science.aax0902.
604 26. Saraswati, K., Phanichkrivalkosil, M., Day, N. P. J. & Blacksell, S. D. The validity
605 of diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG
606 ELISAs: A review of the evidence. *PLoS Negl. Trop. Dis.* (2019)
607 doi:10.1371/journal.pntd.0007158.
608 27. Xu, H., Lohr, J. & Greiner, M. The selection of ELISA cut-off points for testing
609 antibody to Newcastle disease by two-graph receiver operating characteristic
610 (TG-ROC) analysis. *J. Immunol. Methods* (1997) doi:10.1016/S0022-
611 1759(97)00128-2.
612 28. Greiner, M., Franke, C. R., Böhning, D. & Schlattmann, P. Construction of an
613 intrinsic cut-off value for the sero-epidemiological study of Trypanosoma evansi
614 infections in a canine population in Brazil: a new approach towards an unbiased
615 estimation of prevalence. *Acta Trop.* (1994) doi:10.1016/0001-706X(94)90044-
616 2.
617 29. Aghaeepour, N. *et al.* An immune clock of human pregnancy. *Sci. Immunol.*
618 (2017) doi:10.1126/sciimmunol.aan2946.
619 30. Mor, G. & Cardenas, I. The Immune System in Pregnancy: A Unique
620 Complexity. *American Journal of Reproductive Immunology* (2010)
621 doi:10.1111/j.1600-0897.2010.00836.x.
622 31. Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. *New*
623 *England Journal of Medicine* (2014) doi:10.1056/NEJMra1213566.
624 32. Hanke, L. *et al.* An alpaca nanobody neutralizes SARS-CoV-2 by blocking
625 receptor interaction. *bioRxiv* (2020) doi:10.1101/2020.06.02.130161.
626 33. Cervia, C. *et al.* Systemic and mucosal antibody secretion specific to SARS-
627 CoV-2 during mild versus severe COVID-19. *bioRxiv* (2020)
628 doi:10.1101/2020.05.21.108308.
629 34. Eto, D. *et al.* IL-21 and IL-6 are critical for different aspects of B cell immunity
630 and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation.
631 *PLoS One* **6**, e17739 (2011).

632 35. Dienz, O. *et al.* The induction of antibody production by IL-6 is indirectly
633 mediated by IL-21 produced by CD4 + T cells. *J. Exp. Med.* (2009)
634 doi:10.1084/jem.20081571.
635 36. Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell
636 IgG production in a feed-forward proinflammatory mechanism to skew
637 hematopoiesis and elevate myeloid production. *Blood* (2010)
638 doi:10.1182/blood-2009-07-230631.
639 37. Beagley, K. W. *et al.* Interleukins and IgA synthesis. Human and murine
640 interleukin 6 induce high rate IgA secretion in IgA-committed B cells. *J. Exp.*
641 *Med.* (1989) doi:10.1084/jem.169.6.2133.
642 38. Mauer, J. *et al.* Signaling by IL-6 promotes alternative activation of macrophages
643 to limit endotoxemia and obesity-associated resistance to insulin. *Nat. Immunol.*
644 (2014) doi:10.1038/ni.2865.
645 39. Kristiansen, O. P. & Mandrup-Poulsen, T. Interleukin-6 and diabetes: The good,
646 the bad, or the indifferent? *Diabetes* (2005)
647 doi:10.2337/diabetes.54.suppl_2.S114.
648 40. Ferreira, R. C. *et al.* Functional IL6R 358Ala Allele Impairs Classical IL-6
649 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases.
650 *PLoS Genet.* **9**, (2013).
651 41. Park, W. Y. *et al.* Cytokine balance in the lungs of patients with acute respiratory
652 distress syndrome. *Am. J. Respir. Crit. Care Med.* (2001)
653 doi:10.1164/ajrccm.164.10.2104013.
654 42. Magro, G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion'
655 of ARDS onset? What is there besides Tocilizumab? SGP130Fc. *Cytokine: X*
656 (2020) doi:10.1016/j.cytox.2020.100029.
657 43. Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium–immune
658 cell interactions identified by single-cell analysis. *Nat. Biotechnol.* (2020)
659 doi:10.1038/s41587-020-0602-4.
660 44. Jin, J. M. *et al.* Gender Differences in Patients With COVID-19: Focus on
661 Severity and Mortality. *Front. Public Heal.* (2020)
662 doi:10.3389/fpubh.2020.00152.
663 45. Takaki, A. *et al.* Cellular immune responses persist and humoral responses
664 decrease two decades after recovery from a single-source outbreak of hepatitis
665 C. *Nat. Med.* (2000) doi:10.1038/75063.
666 46. Schroeder, H. W. & Cavacini, L. Structure and function of immunoglobulins. *J.*
667 *Allergy Clin. Immunol.* (2010) doi:10.1016/j.jaci.2009.09.046.
668 47. Christian, M. & Murrell, B. Discriminative Bayesian Serology: Counting Without
669 Cutoffs. *BioRxiv* (2020).
670 48. Behring & Kitasato. Ueber das Zustandekommen der Diphtherie-Immunitüt und
671 der Tetanus-Immunitüt bei Thieren. *Dtsch. Medizinische Wochenschrift* (1890)
672 doi:10.1055/s-0029-1207589.
673 49. Plotkin, S. A. Vaccines: Correlates of Vaccine-Induced Immunity. *Clin. Infect.*
674 *Dis.* (2008) doi:10.1086/589862.
675 50. Larios Mora, A. *et al.* Delivery of ALX-0171 by inhalation greatly reduces
676 respiratory syncytial virus disease in newborn lambs. *MAbs* (2018)
677 doi:10.1080/19420862.2018.1470727.
678 51. Sheridan, C. Ablynx's nanobody fragments go places antibodies cannot. *Nat.*
679 *Biotechnol.* (2017) doi:10.1038/nbt1217-1115.

52. Hurst, S. M. *et al.* IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. *Immunity* **14**, 705–714 (2001).
53. Pedersen, B. K. IL-6 signalling in exercise and disease. in *Biochemical Society Transactions* (2007). doi:10.1042/BST0351295.
54. Intensivvårdsregistret, S. Antal som intensivvårdas med Covid-19 per dag. *Svenska Intensivvårdsregistrets utdataportal* https://portal.icuregswe.org/siri/report/corona.co (2020).
55. Paterlini, M. 'Closing borders is ridiculous': the epidemiologist behind Sweden's controversial coronavirus strategy. *Nature* (2020) doi:10.1038/d41586-020-01098-x.
56. Platt, J. & others. Probabilistic outputs for support vector machines and comparisons to regularized likelihood methods. *Adv. large margin Classif.* (1999).
57. Lott, A. & Reiter, J. P. Wilson Confidence Intervals for Binomial Proportions With Multiple Imputation for Missing Data. *Am. Stat.* (2020) doi:10.1080/00031305.2018.1473796.



Figure 1: Patient, blood donor and pregnant women anti-SARS-CoV-2 antibody phenotypes

(**A**) Log transformed anti-S and -RBD IgG responses are shown in COVID-19 patients (*n*=105), blood donors (BD, *n*=1,000) and pregnant women (PW, *n*=900). Controls (C) represent *n*=295 individuals analyzed repeatedly (to *n*=890). (**B**) IgM, IgG and IgA responses against S and RBD in COVID-19 patients (*n*=105), with a limited number of controls for each assay represented by open circles. (**C**) COVID-19 patient (*n*=105) anti-viral antibody levels and serum IL-6 levels according to clinical disease severity. S and RBD responses are graphed together, alongside a limited number of controls. (**D**) Three longitudinal patient profiles of seroconversion and neutralisation capacity are shown in hospitalized individuals.

A

	d-p SymO	d-p PCR	DOB	Sex	Severity	IL-6	PSV ID50	S IgM	RBD IgM	S IgG	RBD IgG	S IgA	RBD IgA
d-p SymO	1.000	0.925	-0.028	-0.046	-0.074	0.007	-0.034	-0.288	-0.314	0.217	-0.043	-0.269	-0.309
d-p PCR	0.925	1.000	0.025	-0.117	-0.169	-0.069	-0.155	-0.388	-0.433	0.139	-0.148	-0.354	-0.411
DOB	-0.028	0.025	1.000	-0.206	-0.303	-0.317	-0.240	-0.213	-0.246	-0.186	-0.181	-0.166	-0.220
Sex	-0.046	-0.117	-0.206	1.000	0.261	0.360	0.024	0.106	0.171	0.063	0.179	0.274	0.360
Severity	-0.074	-0.169	-0.303	0.261	1.000	0.710	0.432	0.250	0.312	0.397	0.400	0.604	0.503
IL-6	0.007	-0.069	-0.317	0.360	0.710	1.000	0.196	0.081	0.113	0.213	0.225	0.438	0.346
PSV ID50	-0.034	-0.155	-0.240	0.024	0.432	0.196	1.000	0.681	0.738	0.543	0.766	0.615	0.659
S IgM	-0.288	-0.388	-0.213	0.106	0.250	0.081	0.681	1.000	0.919	0.414	0.600	0.551	0.549
RBD IgM	-0.314	-0.433	-0.246	0.171	0.312	0.113	0.738	0.919	1.000	0.353	0.567	0.520	0.570
S IgG	0.217	0.139	-0.186	0.063	0.397	0.213	0.543	0.414	0.353	1.000	0.683	0.532	0.437
RBD IgG	-0.043	-0.148	-0.181	0.179	0.400	0.225	0.766	0.600	0.567	0.683	1.000	0.708	0.707
S IgA	-0.269	-0.354	-0.166	0.274	0.604	0.438	0.615	0.551	0.520	0.532	0.708	1.000	0.902
RBD IgA	-0.309	-0.411	-0.220	0.360	0.503	0.346	0.659	0.549	0.570	0.437	0.707	0.902	1.000

-1.0 -0.5 0 0.5 1.0

B



Figure 2: Antibody-clinical feature associations in COVID-19 patients

(**A**) Spearman's rank correlation of patient dataset features and antibody levels. DOB - *date of birth*; d-p SymO - *days post-symptom onset*; d-p PCR – *days post SARS-CoV-2+ PCR*; PSV ID50 – *neutralizing titer* (**B**) Adjusted fold change for dataset features in COVID-19 patients compared to category 1 individuals. The effects of age (DOB), sex, days from PCR test were considered.



Figure 3: *In vitro* virus neutralizing responses

(**A**) Pseudotyped virus neutralization by serial dilutions of serum from COVID-19 patients (*n*=48, *red*), blood donors (*blue*) and pregnant women (*purple*). (**B**) Neutralization ID_{50} titers according to disease severity category. (**C**) Comparison of neutralization ID_{50} titers between patients, blood donors and pregnant women. (**D**) Correlation between anti-S and -RBD IgM, IgG and IgA antibodies and neutralisation titers.



Figure 4: Probability-based seroprevalence in Stockholm during the height of the pandemic

(**A**) Study sample collection intervals are shown alongside the rolling weekly average COVID-19 deaths per million inhabitants in relevant countries for comparison. (**B**) By randomly selecting six groups of 20 negative controls from a pool of 890 values (from n=295 individuals), the range of the 6SD cut-off is shown to significantly affect positivity estimates in healthy donors (HD) from weeks 17-19 2020. (**C**) Using a conventional 6SD cut-off, we found 6.2, 6.5 and 7.7% of healthy donors to be antibody-positive in weeks 17-19, 20-22 and 23-25, respectively. (**D**) Seroprevalence estimates in healthy donor cohorts through time using a cut-off-independent Bayesian approach. (**E**) An ensemble SVM-LDA learner trained on our patient data illustrates the problem of weak responders and provides a multi-dimensional solution by providing individual datapoints with a likelihood of positivity, a feature with potential for clinical use.

Table 1 – Study patient, blood donor and pregnant women characteristics

COVID-19 patients (n=)		105
Females		44 (41.9%)
Males		61 (58.1%)
Median age (years)*		53.0 (49-61)
	Females	51.5 (48-56.2)
	Males	55.0 (49-63)
Non-hospitalized		53 (50.5%)
	Females, males	28, 25
Hospitalized		31 (29.5%)
	Females, males	12, 17
Intensive care (ICU)		21 (20%)
	Females, males	3, 17
Disease category unknown		2 (1.9%)
	Females, males	1, 1
SARS-CoV2+ PCR		105
Sample collection dates		February-June 2020
Blood donors (n=)		1,000
Median age (years)		N/A
Sex		N/A
SARS-CoV2+ PCR		N/A
Sample collection dates		Weeks 14-25 2020
Pregnant women (n=)		900
Age (years)		N/A
SARS-CoV2+ PCR		N/A
Sample collection dates		Weeks 17-25 2020
Historical blood donors (n=)		295
Median age (years)		N/A
Sex		N/A
SARS-CoV2+ PCR		No
Sample collection dates		Spring 2019
**LQR-UQR given in brackets*		

Table 1



Figure S1: Anti-SARS-CoV-2 ELISA protocol development

(**A**) Trimeric S and RBD were expressed in 293F cells and purified as described. (**B**) A subset of patients and negative controls was used to validate the assays for the three isotypes. (**C**) Two ECV+ donors, K2 and K4, showed reproducible IgM binding to S, please refer to their increased responses to S and nucleocapsid in S2. Testing another subset of historical controls (*n*=75) for a similar observation, two additional individuals were found to show IgM binding to S.



Figure S2: Patient binding titrations

A subset (*n*=40) PCR+ COVID-19 patients were titrated in our assay. Shown are these responses against the three antigens and isotypes in the study. Four ECV+ (red lines) were in a similar dilution series alongside.



Figure S3: Healthy donor and patient antibody phenotypes

(**A**) Raw OD450 anti-S and -RBD IgG responses are shown for patients and healthy donors. (**B**) Raw OD450 isotypic responses in patients against S and RBD. A limited number of negative controls are depicted by clear circles. (**C**) Anti-S vs -RBD responses in COVID-19 patients are highly correlated. (**D**) Log transformed patient anti-S and -RBD levels according to disease severity by isotype. *P* values from a Cuzick test for trend.



Figure S4: Patient antibody phenotypes

(**A**) Antibody responses according to sex are shown (left panel) and severity (right panel). *P* values from a Kruskal Wallis or stratified Mann-Whitney, as shown. (**B**) Lower levels of IgA were observed in a subset (*n*=100) of blood donors and pregnant women. Patient (P) and healthy donor (HD) responses to S and RBD are shown. (**C**) IgM and IgA titers declined with time from first symptom/SARS-CoV-2+ PCR and admittance to care. IgG levels were maintained. *P* values from a Spearman rank correlation test. (**D**) Patient sampling according to date since PCR+ test shown for anti-viral IgM responses. (**E**) Longitudinal profiles of category 1 and 2 patients after seroconversion.

A



B



Figure S5: Comparison of cut-off-independent machine learning methods

(**A**) Overlay and agreement of SVM-LDA ensemble learner predictions with our Bayesian framework. (**B**) Seroprevalence changes over time follow a very similar trajectory to Stockholm County deaths when lagged by 2.5 weeks.